<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9A33F2AD-93B0-44C1-AD2C-F84E66162907"><gtr:id>9A33F2AD-93B0-44C1-AD2C-F84E66162907</gtr:id><gtr:name>University of Udine</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/FE8EF780-983C-4E93-BBAD-A06CCAA42EC0"><gtr:id>FE8EF780-983C-4E93-BBAD-A06CCAA42EC0</gtr:id><gtr:name>University of Genoa</gtr:name><gtr:address><gtr:line1>5 Via Balbi</gtr:line1><gtr:line4>I-16126 Genoa</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AFBF2A7E-9CB1-4B05-A7C8-88903332FF09"><gtr:id>AFBF2A7E-9CB1-4B05-A7C8-88903332FF09</gtr:id><gtr:name>Cochin Institute</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:department>Medicine</gtr:department><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9A33F2AD-93B0-44C1-AD2C-F84E66162907"><gtr:id>9A33F2AD-93B0-44C1-AD2C-F84E66162907</gtr:id><gtr:name>University of Udine</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/FE8EF780-983C-4E93-BBAD-A06CCAA42EC0"><gtr:id>FE8EF780-983C-4E93-BBAD-A06CCAA42EC0</gtr:id><gtr:name>University of Genoa</gtr:name><gtr:address><gtr:line1>5 Via Balbi</gtr:line1><gtr:line4>I-16126 Genoa</gtr:line4><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/9EED95BB-25DC-4032-8E45-C3EA7277E78A"><gtr:id>9EED95BB-25DC-4032-8E45-C3EA7277E78A</gtr:id><gtr:name>University of Milan</gtr:name><gtr:address><gtr:line1>Via Festa del Perdono 7</gtr:line1><gtr:postCode>20122</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Italy</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AFBF2A7E-9CB1-4B05-A7C8-88903332FF09"><gtr:id>AFBF2A7E-9CB1-4B05-A7C8-88903332FF09</gtr:id><gtr:name>Cochin Institute</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/4D67F37C-3000-4234-BA3F-23A6C528D090"><gtr:id>4D67F37C-3000-4234-BA3F-23A6C528D090</gtr:id><gtr:firstName>Vittorio</gtr:firstName><gtr:surname>Bellotti</gtr:surname><gtr:roles><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FK000187%2F1"><gtr:id>BB374F1A-E7B6-4580-9603-8D02A19DCA28</gtr:id><gtr:title>Strategic Skills Award</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/K000187/1</gtr:grantReference><gtr:abstractText>Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.</gtr:abstractText><gtr:fund><gtr:end>2015-01-09</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2012-01-10</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>201353</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Structural Molecular Biology</gtr:department><gtr:description>NMR analysis of alpha-synuclein, apolipoprotein C-III and transthyretin (John Christodoulou)</gtr:description><gtr:id>6968ABF6-D5AF-43CF-9157-D1C115F10BDC</gtr:id><gtr:impact>The first manuscript related to the alpha-synuclein project has been already published (PMID 25505181).

The second manuscript on the apolipoprotein C-III has been published on a high impact journal (PMID 26790392).</gtr:impact><gtr:outcomeId>545a78c1d284f6.43671643-1</gtr:outcomeId><gtr:partnerContribution>Christodoulou and colleagues have carried out NMR study of alpha synuclein and apoliprotein-CIII isoforms. 

The new project related to TTR will also involve the full training of Bellotti's PhD student (supported by the recent M427 Rosetrees Trust award) to NMR spectroscopy. Meanwhile another expert in NMR has joined the team. Dr Alessandra Corazza (University of Udine, Italy) will spend two sabbatical years at UCL and will help with the experimental part of the study as well with the training of the student.</gtr:partnerContribution><gtr:piContribution>Bellotti and his group are investigating the mechansim of aggregation of a pathogenic variant of alpha synuclein as part of a major project in collaboration within UCL. Collaboration with Professor John Christodoulou's group has been invaluable for the identification of structural features underlying the peculiar aggregation propensity of this variant. At the same time, our collaboration with Professor Christodoulou has been extended to another project related to a novel variant of apoliprotein C-III which is associated to a new type of hereditary amyloidosis. 

Following Bellotti's seminal discovery of a novel mechano-enzymatic mechanism underlying transthyretin (TTR) amyloidogenesis in vivo (See recent publication in EMBO Mol Med, 2015) a new project has started to characterize this novel molecular mechanism by NMR using the highly amyloidogenic recombinant Ser52Pro TTR. The project will be very challenging and ultimately NMR will be used to study the binding of TTR by ligands and their potential inhibitory effect on proteolysis and fibrillogenesis.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Institute of Neurology</gtr:department><gtr:description>Aggregation propensity of alpha synuclein (Anthony Schapira)</gtr:description><gtr:id>F49AF2EC-814C-44F1-8FC9-AAC9B27BE598</gtr:id><gtr:impact>A first manuscript submitted to J Biol Chem has been published (PMID 25505181). 
Latest findings linking alpha-synuclein scavenging activity with brain lipid composition suggest a possible etiological mechanism in some neurodegenerative disorders. This stdy has been recenly published on J Biol Chem (PMID 28232489)

Following this first publication Bellotti kept on collaborating with Schapira on a grant application which was finally funded by MRC: MR/M006646/1; GRANT TITLE: Glucocerebrosidase mutations in Parkinson disease: molecular pathogenesis, and the basis for personalised therapy with small molecule chaperones.
Start date: 01/09/2014; End date: 31/08/2018; &amp;pound; 954,360
PI: Anthony Schapira; Co-applicants: Prof V Bellotti, Dr DA Hughes, Prof AB Mehta, Prof M Spillantini</gtr:impact><gtr:outcomeId>545a7df93decf3.26667077-1</gtr:outcomeId><gtr:partnerContribution>Professor Schapira and his group have identified the H50Q variant alpha synuclein. They are one of the group leaders in the study of molecular and clinical aspects of Parkinson's disease.</gtr:partnerContribution><gtr:piContribution>Bellotti and his group has investigated the mechanism of aggregation of a novel pathogenic variant of alpha-synuclein, H50Q, in direct comparison with the wild type counterpart as a major project of collaboration within UCL.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2013-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cochin Institute (Institut Cochin)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Laboratoire de Biochimie et G?n?tique Mol?culaire</gtr:department><gtr:description>Novel amyloidogenic variant of ?2-microglobulin and apolipoprotein-CIII (Sophie Valleix)</gtr:description><gtr:id>06ADED1E-F3D2-49FB-80B7-0C8D2F813526</gtr:id><gtr:impact>Three publications (PMID: 26790392, 22693999, 24014031) have resulted from this collaboration.

The manuscript on the novel amyloidogenic variant of apolipoprotein-CIII has just been published on Nature Communications (see publications).</gtr:impact><gtr:outcomeId>UVWacKFZpss-1</gtr:outcomeId><gtr:partnerContribution>Dr Valleix was the lead clinician involved in the identification of both the novel amyloidogenic variant ?2-microglobulin and apolipoprotein-CIII in patients at her clinical centre.</gtr:partnerContribution><gtr:piContribution>This was a major achievement of Bellotti and his group. Following the initial identification of the first ever amyloidogenic variant of ?2-microglobulin (D76N ?2-microglobulin) in a French family, we fully characterised the protein and identified its mechanism of fibrillogenesis under physiological conditions. This has now allowed us to identify some of the forces involved in triggering amyloidogenesis in vivo. The collaboration has now been extended to a novel amyloidogenic variant of apoliprotein-CIII for which Bellotti has characterized its aggregation propensity compared to the wild type counterpart under physiological conditions.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Genoa</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Physics</gtr:department><gtr:description>Atomic force microscopy in amyloid (Annalisa Relini)</gtr:description><gtr:id>AE4FE172-94F0-4181-8D16-E9EDE388DD02</gtr:id><gtr:impact>14 Publications (PMID: 26790392, 25505181, 24474780, 24014031, 22271711, 21296086, 21068391, 21067308, 19626482, 18056266, 17242436, 16601119, 15337168, 25505181)</gtr:impact><gtr:outcomeId>jZ6vH5i1sYN-1</gtr:outcomeId><gtr:partnerContribution>The application of atomic force microscopy for the analysis of amyloid fibrils from wild type and D76N ?2-microglobulin, Leu174Ser ApolipoproteinA-I, abeta peptide, a -synuclein, apolipoprotein C-III, all prepared by the Bellotti group.</gtr:partnerContribution><gtr:piContribution>We have always tried to identify new techniques to better understand the mechanisms of amyloid formation. In this case, we initiated acollaboration with Annalisa Relini and colleagues, using atomic force microscopy to examine the structure of amyloid fibrils during their growth, from a range of precursor proteins which we have intensively studied over the past years; these include Apolipoprotein A-I, abeta peptide, transthyretin, a -synuclein, apolipoprotein C-III, wild type and D76N ?2-microglobulin.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Centre for Amyloidosis and Acute Phase Proteins</gtr:department><gtr:description>Amyloidosis and drug development (CAAPP and NAC)</gtr:description><gtr:id>5BB599A4-935D-4B77-B5A9-1574E32E28E3</gtr:id><gtr:impact>15 Publications (PMID: 26790392, 26400472, 26646718, 26286619, 24474780, 24014031, 22693999, 21059958, 20962779, 19372378, 16642000, 9039909, 8915605, 26286619, 26400472)</gtr:impact><gtr:outcomeId>VQznULg5a2a-1</gtr:outcomeId><gtr:partnerContribution>The UCL Centre for Amyloidosis and Acute Phase Proteins comprises the Wolfson Drug Discovery Unit directed by Prof Sir Mark Pepys FRS FMedSci and the NHS National Amyloidosis Centre headed by Prof Philip Hawkins FMedSci. The clinical and non-clinical groups are closely linked, and allow both groups to share and build upon findings from laboratory-based and clinical (patient based) studies. The UCL transgenic mouse unit (headed by Dr Paul Simons) is central to a number of our projects including the production of transgenic mice expressing pathogenic protein variants such as human D76N ?2-microglobulin (created with the support of Bellotti's MRC Strategic Award) and S52P human transthyretin.</gtr:partnerContribution><gtr:piContribution>Bellotti has had a long-standing and successful collaboration with the Centre for Amyloidosis and Acute Phase Proteins. As a result, he was appointed as Professor of Medical Biochemistry at UCL in October 2011, and now has a team working within the Centre. Apart from his independent work on ?2-microglobulin, transthyretin, a-synuclein and Apolipoprotein CIII, he is also central to a number of the Centre's drug development programmes targeting amyloidosis and other diseases. These include a novel therapy based on antibody-mediated depletion of serum amyloid P component, the stabilisation of transthyretin to reduce protein deposition in vivo and a small molecule inhibitor of C-reactive protein to limit CRP-mediated tissue damage following myocardial infarction. The latest results underlying an unexplored mechanism of transthyretin amyloidogenesis will provide novel drug discoveries targets and offer insight into the mode of action of current approaches based on drugs occupying the thyroxine-binding site.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Udine</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Department of Medical and Biological Sciences</gtr:department><gtr:description>NMR investigation of ?2-microglobulin (Gennaro Esposito)</gtr:description><gtr:id>520946E2-98C6-4561-BB7E-90F81982E728</gtr:id><gtr:impact>28 Publications (PMID: 25695203, 24338476, 24136818, 24014031, 23645685, 23225003, 22522028, 22380530, 21663612, 21287627, 21068391, 20558175, 20028983, 19626482, 18835891, 18395224, 17242436, 17158575, 16601119, 16520957, 16081329, 15689502,14698299, 14660575, 12709420, 11847272, 11266606, 10850793)</gtr:impact><gtr:outcomeId>YLTb4j4LFn1-1</gtr:outcomeId><gtr:partnerContribution>Esposito and colleagues undertook the NMR studies of ?2-microglobulin and all its variants including the natural D76N ?2-microglobulin.</gtr:partnerContribution><gtr:piContribution>We have extensively examined the mechanisms underlying amyloid deposition of ?2-microglobulin in patients with dialysis related amyloidosis. Using a site-directed mutagenesis approach we have systematically prepared a number of variants and studied the folding and misfolding of this protein with different biophysical approaches: NMR has been an invaluable complementary tool for this work. Most recently we have examined the folding and mechanism of fibrillogenesis of the only pathologiocal variant, D76N ?2-microglobulin, as part of this collaboration. Investigation of inhibitors of D76N ?2-microglobulin and their potential exploitation in the treatment of the hereditary systemic amyloidosis related to this variant has been recently included in a manuscript currently under revision.</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Milan</gtr:collaboratingOrganisation><gtr:country>Italy, Italian Republic</gtr:country><gtr:department>Biomolecular Science and Biotechnology</gtr:department><gtr:description>Crystal structure of ?2-microglobulin (Martino Bolognesi)</gtr:description><gtr:id>05A2D71A-08D8-42DF-9F6A-60C63BC91DCF</gtr:id><gtr:impact>17 Publications: (PMID: 27150430, 25102442, 24338476, 22693999, 22500768, 22289140, 21663612, 2159201, 21398368, 20506535, 20356307, 19284997, 18835253, 18395224, 15337168, 14698299, 12832782)</gtr:impact><gtr:outcomeId>YQRqJLhNvEZ-1</gtr:outcomeId><gtr:partnerContribution>Professor Martino Bolognesi is a crystallographer who has worked closely with Bellotti to solve the crystal structure of ?2-microglobulin and its variants.</gtr:partnerContribution><gtr:piContribution>This work is related to our studies into ?2-microglobulin amyloidosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>Recombinant protein expressed in E. coli. Site-directed mutagenesis of pHN1 plasmid encoding wild type ?2-microglobulin was used for mutagenesis of aspartate at position 76 in the wild type sequence into asparagine. A vast repertoire of ?2-microglobulin isoforms is already available in Bellotti's laboratory.</gtr:description><gtr:id>F8BFA670-D213-415A-ABC0-C45455F85346</gtr:id><gtr:impact>Availability of recombinant D76N ?2-microglobulin allowed full structural characterization and study of folding of the variant compared to the wild type ?2-microglobulin.</gtr:impact><gtr:outcomeId>WKWzsdV2Sa6</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>D76N ?2-microglobulin</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establishement of D76N ?2-microglobulin fibrillogenesis under physiological conditions (ionic strength and temperature).</gtr:description><gtr:id>D31592FD-4B8D-43CA-B43B-58EC7570CD17</gtr:id><gtr:impact>Availability of recombinant D76N ?2-microglobulin allowed establishment of a robust and reproducible method of in vitro fibrillogenesis under physiological conditions. This method was essential to analyse the forces triggering fibrillogenesis of D76N ?2-microglobulin and elucidate its mechanism. Private companies have shown interest to use this new technology to evaluate the efficacy of inhibitors of D76N ?2-microglobulin fibrillogenesis.</gtr:impact><gtr:outcomeId>V3oJZDncWU4</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>D76N ?2-microglobulin fibrillogenesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Acellular translucent mouse livers with a conserved vascular tree and the constitutive extracellular matrix (ECM) network have been generated using solutions of sodium deoxycholate and DNase.</gtr:description><gtr:id>974FCAE4-2067-472C-94C6-625BD84F78F5</gtr:id><gtr:impact>This system may represent the most advanced bio-mimetic ex-vivo device for studying the effect of the ECM network in perturbing the structure of native globular amyloidogenic proteins and prime their aggregation. It will be an excellent tool to identify suitable inhibitors of fibrillogenesis.</gtr:impact><gtr:outcomeId>56bb770d3d9f01.03753064</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biological scaffold</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Recombinant wild type and D25V protein variant apolipoprotein C-III (apoC-III) were expressed in E. coli. Wild type ApoC-III was expressed using a pET23b vector containing the full-length cDNA for human ApoC-III, including the sequence encoding a C-terminal His6-tag preceded by Leu and Glu additional residues. 
Site-directed mutagenesis of pET23b plasmid containing the cDNA for wild type ApoC-III was carried out to replace a residue of aspartate into valine in position 25 of the mature protein.</gtr:description><gtr:id>FE350934-1BF3-4232-B193-74962AD73573</gtr:id><gtr:impact>Availability of proteins allows us to confirm the amyloidogenic propensity of D25V variant apoC-III which is the first apoC-III causing hereditary systemic amyloidosis (manuscript published on Nature Communications in 2016).</gtr:impact><gtr:outcomeId>56bb736401ca97.07306983</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Apolipoprotein C-III</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establishment of a method of fibrillogenesis for the novel amyloidogenic D25V variant apolipoprotein C-III under physiological conditions.</gtr:description><gtr:id>8F0C1379-F202-451E-BC9A-FB84525FA72E</gtr:id><gtr:impact>The method will help to understand the mechanism of amyloidogenesis and to identify inhibitors.</gtr:impact><gtr:outcomeId>56bb747bf069d8.17039760</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>D25V apolipoprotein C-III fibrillogenesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establishement of three transgenic C. elegans strains expressing human wild type ?2-microglobulin and two isoforms P32G and ?N6 under the control of the body-wall muscle specific unc-54 promoter/enhancer.</gtr:description><gtr:id>8A9B835B-1BBF-4714-BD3D-8A5820DD84E4</gtr:id><gtr:impact>In absence of any animal model for ?2-microglobulin amyloidosis we have generated transgenic C. elegans model to study protein aggregation and inhibitors. Currently the model is also in use for environmental toxicity studies. In particular results describing the effect of silver nanoparticles on transgenic C. elegans expressing wild type ?2-m in comparison with the ancestral C. elegans strain are now included in a manuscript submitted to Altex. This work demonstrates that C. elegans strains recapitulating molecular events causing Dialysis Related Amyloidosis are a valuable tool to assess toxicity of potentially harmful molecules.</gtr:impact><gtr:outcomeId>B84TDajUeMY</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>C. elegans strains</gtr:title><gtr:type>Model of mechanisms or symptoms - non-mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establishment of a novel method of fibrillogenesis under physiological conditions, i.e. ionic strength and temperature. The outcome followed the identification of a novel mechano-enzymatic mechanism underlying transthyretin (TTR) amyloidogenesis. The method of fibrillogenesis differs from the one already described for S52P TTR for the presence of stirring conditions required to make wild type and the other amyloidogenic TTR isoforms more accessible to enzymatic cleavage (Marcoux et al. EMBO Mol Med, 7:1337-49, 2015).</gtr:description><gtr:id>B0505DA5-F8C1-478B-943F-6BE75DDBD3E7</gtr:id><gtr:impact>Establishement of a novel method of fibrillogenesis under physiological conditions allowed formation of genuine amyloid fibrils for wild type, L55P, V30M, V122I TTR (Marcoux et al. EMBO Mol Med, 7:1337-49, 2015). The procedure will be relevant for the identification of novel drug discovery targets.</gtr:impact><gtr:outcomeId>5617f489c1d887.64294077</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Wild type, L55P, V30M, V122I transthyretin fibrillogenesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Recombinant protein expressed in E. coli. Site-directed mutagenesis of pet11a plasmid encoding wild type transthyretin was used for mutagenesis of serine in position 52 into proline.</gtr:description><gtr:id>147A0D90-1E71-43F9-A0B3-A15060FEB1A7</gtr:id><gtr:impact>The availability of recombinant S52P transthyretin allowed elucidation of mechanism of fibrillogenesis of this pathological variant associated with an extremely aggressive form of hereditary systemic TTR amyloidosis. This work has now been published on Proc Natl Acad Sci USA. We have continued investigating this unexplored pathway of TTR amyloidogenesis for the other most common variants associated to cardiac amyloidosis and a new manuscript has been published on EMBO Molecular Medicine in 2015. The discovery and characterization of this novel mechano-enzymatic cleavage mechanism will be relevant to analyse the mode of action of current therapeutic approaches and provide novel drug discovery targets.</gtr:impact><gtr:outcomeId>aHDu8k5jaJm</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>S52P transthyretin</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Recombinant protein was expressed in E. coli. Site-directed mutagenesis of pT7-7 plasmid encoding wild type alpha-synuclein was used for mutagenesis of histidine at position 50 in the wild type sequence into glutamine.</gtr:description><gtr:id>C6BD4AB9-F19C-4BE5-9676-20F787B16B23</gtr:id><gtr:impact>Availability of recombinant H50Q alpha-synuclein was used to characterize the aggregation propensity, NMR structure and thermodynamic stability of the corresponding H50Q alpha-synuclein fibrils in comparison with the wild type counterpart.</gtr:impact><gtr:outcomeId>545bd0dba07f48.90435010</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>H50Q alpha synuclein</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Establishment of a novel method of fibrillogenesis under physiological conditions, i.e. ionic strength and temperature.</gtr:description><gtr:id>9FACBFFC-33DA-470A-9CC4-0BF010ACAF61</gtr:id><gtr:impact>The establishement of a novel method of fibrillogenesis under physiological conditions allows formation of genuine amyloid fibrils (manuscript published on Proc Natl Acad Sci USA in 2014). The procedure will be relevant for the identification of novel drug discovery targets.</gtr:impact><gtr:outcomeId>mYsMfALz4bo</gtr:outcomeId><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>S52P transthyretin fibrillogenesis</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>30C2683B-C540-4A37-89EC-CAEEFC282BA5</gtr:id><gtr:title>Inhibition of the mechano-enzymatic amyloidogenesis of transthyretin: role of ligand affinity, binding cooperativity and occupancy of the inner channel.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0b4d4f5883940e2f16f6355d33c2490"><gtr:id>f0b4d4f5883940e2f16f6355d33c2490</gtr:id><gtr:otherNames>Verona G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a7dd43bc18058.53237464</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7D3FC517-1338-4B81-AB75-77C4B1132623</gtr:id><gtr:title>Class I major histocompatibility complex, the trojan horse for secretion of amyloidogenic ?2-microglobulin.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f8f4f157aa8d0fcd413850151dc4a3f4"><gtr:id>f8f4f157aa8d0fcd413850151dc4a3f4</gtr:id><gtr:otherNames>Halabelian L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>545bc22536afd0.77157327</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EC6074F-0498-4D91-BF47-EAFF7309CE35</gtr:id><gtr:title>A novel mechano-enzymatic cleavage mechanism underlies transthyretin amyloidogenesis.</gtr:title><gtr:parentPublicationTitle>EMBO molecular medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fe83a38923db5c26f6f6505c46e7ed91"><gtr:id>fe83a38923db5c26f6f6505c46e7ed91</gtr:id><gtr:otherNames>Marcoux J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>1757-4676</gtr:issn><gtr:outcomeId>56165f00dc5c01.50946036</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88DA4FAD-D7C3-421D-AD2A-AD7A5CFDB23D</gtr:id><gtr:title>Benefit of doxycycline treatment on articular disability caused by dialysis related amyloidosis.</gtr:title><gtr:parentPublicationTitle>Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/9c1013d2b8010bce82926486425aa9eb"><gtr:id>9c1013d2b8010bce82926486425aa9eb</gtr:id><gtr:otherNames>Montagna G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1350-6129</gtr:issn><gtr:outcomeId>pm_23443_23_23734692</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A862862-8B5E-4B6F-9AAE-64BA0846FB7C</gtr:id><gtr:title>Systemic amyloidosis: lessons from ?2-microglobulin.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/6802f705af1629706c9a7aaa8958081e"><gtr:id>6802f705af1629706c9a7aaa8958081e</gtr:id><gtr:otherNames>Stoppini M</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_55f9869865f8a2b1</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CF85C5C-B1E9-4FDF-B850-485FB3D2A9BE</gtr:id><gtr:title>Co-fibrillogenesis of Wild-type and D76N ?2-Microglobulin: THE CRUCIAL ROLE OF FIBRILLAR SEEDS.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/deaa7d3c6534223e90bc38ef04401767"><gtr:id>deaa7d3c6534223e90bc38ef04401767</gtr:id><gtr:otherNames>Natalello A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>585d3747d1a745.31741754</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88BB1BFB-2556-4D72-BEC9-8B3D334D58C9</gtr:id><gtr:title>Rapid proton-detected NMR assignment for proteins with fast magic angle spinning.</gtr:title><gtr:parentPublicationTitle>Journal of the American Chemical Society</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e82f21bd53156aea3b4b05b9282a2d93"><gtr:id>e82f21bd53156aea3b4b05b9282a2d93</gtr:id><gtr:otherNames>Barbet-Massin E</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-7863</gtr:issn><gtr:outcomeId>545bc4ab4e3ab6.99561829</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>47A0F1D0-68C9-4975-B1F4-7D9A8AB042C1</gtr:id><gtr:title>Hereditary systemic amyloidosis due to Asp76Asn variant ?2-microglobulin.</gtr:title><gtr:parentPublicationTitle>The New England journal of medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0f47e4a8312b89acfbcc528be608827"><gtr:id>b0f47e4a8312b89acfbcc528be608827</gtr:id><gtr:otherNames>Valleix S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0028-4793</gtr:issn><gtr:outcomeId>pm_23443_23_22693999</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>4B6B8071-D59A-456E-BE0B-3B12F2BA3652</gtr:id><gtr:title>A specific nanobody prevents amyloidogenesis of D76N ?-microglobulin in vitro and modifies its tissue distribution in vivo.</gtr:title><gtr:parentPublicationTitle>Scientific reports</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/dc095e16e47b8f3f9cd33fe598ce30e1"><gtr:id>dc095e16e47b8f3f9cd33fe598ce30e1</gtr:id><gtr:otherNames>Raimondi S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2045-2322</gtr:issn><gtr:outcomeId>5a7dd41185a6c7.38406266</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>BC116A49-E6E0-4E8D-BECA-031537EF0CD7</gtr:id><gtr:title>a-Synuclein structural features inhibit harmful polyunsaturated fatty acid oxidation, suggesting roles in neuroprotection.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/63e5cc7e7d6b506f69ee11d57a950190"><gtr:id>63e5cc7e7d6b506f69ee11d57a950190</gtr:id><gtr:otherNames>De Franceschi G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>58b824fb0e1d26.67024407</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>71EFB28E-F6D3-486E-BD9B-2CD32B3B7949</gtr:id><gtr:title>Historical and Current Concepts of Fibrillogenesis and In vivo Amyloidogenesis: Implications of Amyloid Tissue Targeting.</gtr:title><gtr:parentPublicationTitle>Frontiers in molecular biosciences</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/a266a3d152a3d1cd2b2abb5bebb479cc"><gtr:id>a266a3d152a3d1cd2b2abb5bebb479cc</gtr:id><gtr:otherNames>Kisilevsky R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2296-889X</gtr:issn><gtr:outcomeId>58b8246e7c16d2.10740335</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C60FC6A9-B6D4-4A5F-A41F-31F9B4DD1D6E</gtr:id><gtr:title>The H50Q mutation induces a 10-fold decrease in the solubility of a-synuclein.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/3f7aa6444d5dff6d96f0e0532bed12c1"><gtr:id>3f7aa6444d5dff6d96f0e0532bed12c1</gtr:id><gtr:otherNames>Porcari R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>doi_55faa2aa24c13364</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E08A126B-C08F-4AD2-A503-657781E17F01</gtr:id><gtr:title>Amyloid persistence in decellularized liver: biochemical and histopathological characterization.</gtr:title><gtr:parentPublicationTitle>Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/5b3c5c94d97a340a7aaf52ef5525306d"><gtr:id>5b3c5c94d97a340a7aaf52ef5525306d</gtr:id><gtr:otherNames>Mazza G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1350-6129</gtr:issn><gtr:outcomeId>56bb5e30b44ff8.90844104</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3C6E83EE-349F-47D7-80F4-5A1830396F1A</gtr:id><gtr:title>Monitoring the interaction between ?2-microglobulin and the molecular chaperone aB-crystallin by NMR and mass spectrometry: aB-crystallin dissociates ?2-microglobulin oligomers.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b1a6946a2e59ba34ef9ae0367820d596"><gtr:id>b1a6946a2e59ba34ef9ae0367820d596</gtr:id><gtr:otherNames>Esposito G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>545ccdc21ca359.99807325</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0A59380C-04C5-4E8D-BAD4-72035BB8BCF2</gtr:id><gtr:title>Structure, folding dynamics, and amyloidogenesis of D76N ?2-microglobulin: roles of shear flow, hydrophobic surfaces, and a-crystallin.</gtr:title><gtr:parentPublicationTitle>The Journal of biological chemistry</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a12cb17317ac844dd3c546061d293c"><gtr:id>56a12cb17317ac844dd3c546061d293c</gtr:id><gtr:otherNames>Mangione PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0021-9258</gtr:issn><gtr:outcomeId>pm_23443_23_24014031</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C3157F7E-87EE-49D3-97B7-756C5F4B551B</gtr:id><gtr:title>C. elegans expressing human ?2-microglobulin: a novel model for studying the relationship between the molecular assembly and the toxic phenotype.</gtr:title><gtr:parentPublicationTitle>PloS one</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/d4f558a1f15a4bb5e390405f30c34802"><gtr:id>d4f558a1f15a4bb5e390405f30c34802</gtr:id><gtr:otherNames>Diomede L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1932-6203</gtr:issn><gtr:outcomeId>pm_23443_23_23284985</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2C505A67-B828-4D73-A836-8A886CF45D3F</gtr:id><gtr:title>D25V apolipoprotein C-III variant causes dominant hereditary systemic amyloidosis and confers cardiovascular protective lipoprotein profile.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/b0f47e4a8312b89acfbcc528be608827"><gtr:id>b0f47e4a8312b89acfbcc528be608827</gtr:id><gtr:otherNames>Valleix S</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>56bb5e30e23b20.23311543</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>FFB7647D-E593-4DFE-ADD1-6EE91E64736E</gtr:id><gtr:title>Proteolytic cleavage of Ser52Pro variant transthyretin triggers its amyloid fibrillogenesis.</gtr:title><gtr:parentPublicationTitle>Proceedings of the National Academy of Sciences of the United States of America</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a12cb17317ac844dd3c546061d293c"><gtr:id>56a12cb17317ac844dd3c546061d293c</gtr:id><gtr:otherNames>Mangione PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0027-8424</gtr:issn><gtr:outcomeId>pm_540e195e1955e1931</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7EE0A01F-07BC-4980-A5D5-F53AED6FB8DD</gtr:id><gtr:title>Increasing the accuracy of proteomic typing by decellularisation of amyloid tissue biopsies.</gtr:title><gtr:parentPublicationTitle>Journal of proteomics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/56a12cb17317ac844dd3c546061d293c"><gtr:id>56a12cb17317ac844dd3c546061d293c</gtr:id><gtr:otherNames>Mangione PP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1874-3919</gtr:issn><gtr:outcomeId>5a2fd3b925cc22.81941334</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/K000187/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>8F896112-5A04-4A11-A9F0-2B446D9AAC8A</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.1  Pharmaceuticals</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>